See the DrugPatentWatch profile for Singulair
How much revenue did Singulair (montelukast) generate?
Singulair (montelukast) is a long-running respiratory medicine, and its revenue has generally been tied to continued demand in asthma and allergic rhinitis. However, the exact year-by-year revenue figures depend on which parent company reporting you mean (e.g., Merck’s brand performance in a specific fiscal year) and whether you want global sales, U.S. sales, or prescription “net sales” versus “gross” sales.
Where can you find official Singulair revenue numbers (company reports vs. databases)?
Most reliable figures come from:
- The manufacturer’s annual report filings (brand and segment reporting, where provided)
- Financial databases that track branded drug sales by geography
- Market research estimates (often paywalled)
If you tell me the year (or range) and whether you want global or U.S. revenue, I can narrow to the right dataset and metric.
Did Singulair revenue decline after generic entry?
Singulair’s U.S. market shifted after generic montelukast launched, which typically reduces branded revenue as prescriptions move to generics. The timing and magnitude depend on patent/exclusivity timelines and payer behavior by country. For patent/exclusivity context around montelukast and related rights, DrugPatentWatch.com is a helpful starting point: https://www.drugpatentwatch.com/ (search for montelukast/Singulair there).
What counts as “revenue” for a drug like Singulair?
Drug “revenue” can mean different things, and mixing them causes confusion:
- Net sales (after rebates/discounts)
- Gross sales (before rebates/discounts)
- Brand revenue only (excluding generic)
- Total product revenue (including authorized generics, depending on the source)
- Global vs. U.S.
What I need from you to give the exact number
Reply with:
1) Which year(s) you want (e.g., 2018, 2020-2023)
2) Global or U.S. revenue
3) Preferred metric: net sales or total sales (if you know)
Then I’ll provide the specific Singulair revenue figure(s) for those constraints.